Deep mutagenesis scanning using whole trimeric SARS-CoV-2 spike highlights the importance of NTD-RBD interactions in determining spike phenotype
暂无分享,去创建一个
[1] P. Bieniasz,et al. Molecular fate-mapping of serum antibody responses to repeat immunization , 2023, Nature.
[2] Peng Wang,et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution , 2022, bioRxiv.
[3] Timothy C. Yu,et al. A pseudovirus system enables deep mutational scanning of the full SARS-CoV-2 spike , 2022, Cell.
[4] A. Walls,et al. Deep mutational scans for ACE2 binding, RBD expression, and antibody escape in the SARS-CoV-2 Omicron BA.1 and BA.2 receptor-binding domains , 2022, bioRxiv.
[5] J. Zahradník,et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5 , 2022, Cell.
[6] A. Shepherd,et al. Evolutionary remodelling of N‐terminal domain loops fine‐tunes SARS‐CoV‐2 spike , 2022, EMBO reports.
[7] O. Pybus,et al. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa , 2022, Nature Medicine.
[8] Kenneth A. Matreyek,et al. Probing the biophysical constraints of SARS-CoV-2 spike N-terminal domain using deep mutational scanning , 2022, bioRxiv.
[9] B. Meng,et al. SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity , 2022, bioRxiv.
[10] Thomas H. Segall-Shapiro,et al. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein , 2022, bioRxiv.
[11] Kenneth A. Matreyek,et al. Shifting mutational constraints in the SARS-CoV-2 receptor-binding domain during viral evolution , 2022, bioRxiv.
[12] E. Wherry,et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals , 2022, Cell.
[13] Frances E. Muldoon,et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity , 2022, Nature.
[14] Mark M. Davis,et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination , 2022, Cell.
[15] T. Ndung’u,et al. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape , 2022, Cell Host & Microbe.
[16] J. Ball,et al. In vitro evolution predicts emerging SARS-CoV-2 mutations with high affinity for ACE2 and cross-species binding , 2021, bioRxiv.
[17] T. Ndung’u,et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization , 2021, Nature.
[18] Fei Shao,et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.
[19] M. Kraemer,et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa , 2021, Nature.
[20] E. Wherry,et al. Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals , 2021, medRxiv.
[21] M. Koopmans,et al. The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology , 2021, Nature Medicine.
[22] G. Barton,et al. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics , 2021, eLife.
[23] Rommie E. Amaro,et al. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma , 2021, Proceedings of the National Academy of Sciences.
[24] O. Dym,et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution , 2021, Nature Microbiology.
[25] S. Singh,et al. SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India , 2021, Microorganisms.
[26] J. Bloom,et al. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection , 2021, Science Translational Medicine.
[27] William T. Harvey,et al. SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.
[28] J. Skehel,et al. Evolution of the SARS-CoV-2 spike protein in the human host , 2021, Nature Communications.
[29] Adam S. Dingens,et al. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016 , 2021, Cell Reports Medicine.
[30] Ilya J. Finkelstein,et al. Rapid characterization of spike variants via mammalian cell surface display , 2021, bioRxiv.
[31] A. Godzik,et al. Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.
[32] Sergei L. Kosakovsky Pond,et al. Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.
[33] J. Lebbink,et al. Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants , 2021, bioRxiv.
[34] Adam S. Dingens,et al. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016 , 2021, bioRxiv.
[35] E. Procko,et al. An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants , 2021, Science Advances.
[36] Graham W. Taylor,et al. SARS-CoV-2 evolution during treatment of chronic infection , 2021, Nature.
[37] J. Bloom,et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 , 2021, Science.
[38] M. Beltramello,et al. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2 , 2021, bioRxiv.
[39] D. Ho,et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite , 2021, bioRxiv.
[40] J. Bloom,et al. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies , 2021, bioRxiv.
[41] J. Bloom,et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19 , 2020, bioRxiv.
[42] Mitchell H. Murdock,et al. mGreenLantern: a bright monomeric fluorescent protein with rapid expression and cell filling properties for neuronal imaging , 2020, Proceedings of the National Academy of Sciences.
[43] Gaurav D. Gaiha,et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host , 2020, The New England journal of medicine.
[44] E. Fischer,et al. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer , 2020, Cell.
[45] E. Procko,et al. An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants , 2020, bioRxiv.
[46] Sarah K. Hilton,et al. Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding , 2020, Cell.
[47] J. Dye,et al. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2 , 2020, Science.
[48] Shuwen Liu,et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19 , 2020, Acta Pharmacologica Sinica.
[49] G. Ippolito,et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes , 2020, Science.
[50] Jie Zhou,et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice , 2020, Nature Communications.
[51] Jie Zhou,et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice , 2020, Nature Communications.
[52] R. Welsh,et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail , 2020, Science.
[53] Linqi Zhang,et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.
[54] Diwakar Shukla,et al. Structural architecture of a dimeric class C GPCR based on co-trafficking of sweet taste receptor subunits , 2019, The Journal of Biological Chemistry.
[55] M. E. Francis,et al. Back to the Future for Influenza Preimmunity—Looking Back at Influenza Virus History to Infer the Outcome of Future Infections , 2019, Viruses.
[56] E. Procko,et al. Mapping Interaction Sites on Human Chemokine Receptors by Deep Mutational Scanning , 2018, The Journal of Immunology.
[57] F. Ferrara,et al. Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis , 2018, Methods and protocols.
[58] J. Bloom,et al. Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody. , 2017, Cell host & microbe.
[59] Marten Postma,et al. mScarlet: a bright monomeric red fluorescent protein for cellular imaging , 2016, Nature Methods.
[60] Jesse D. Bloom,et al. An Experimentally Determined Evolutionary Model Dramatically Improves Phylogenetic Fit , 2014, bioRxiv.
[61] Bartek Wilczynski,et al. Biopython: freely available Python tools for computational molecular biology and bioinformatics , 2009, Bioinform..